Indianapolis, IN Clinical Trials Report — May 2026

For Indianapolis residents considering participation in clinical research, May 2026 offers both urgent opportunities and significant new avenues to contribute to medical science. Across the city, a notable number of trials are nearing their enrollment deadlines, making prompt action essential for interested individuals.

A total of 57 clinical trials in Indianapolis are slated to conclude within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 8 of these rapidly closing studies are still actively seeking participants without specific health conditions. These trials offer a chance to contribute to medical advancements before their enrollment windows close.

Impending Deadlines for Key Health Areas

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Cystic fibrosis (CF) (2 trials)
• Advanced solid tumor (2 trials)
• Gastroparesis (2 trials)
• Pain (2 trials)
• Amputation, wound (1 trial)
• Amyotrophic lateral sclerosis (1 trial)
• Alzheimer's disease (1 trial)
• Cardiovascular (1 trial)
• Amputation, traumatic/surgery (1 trial)
• Cerebrospinal fluid leakage (1 trial)

New Research Opportunities Emerge

This month, Indianapolis saw the opening of 7 new clinical trials. This is a slight decrease from the 9 new trials that launched in March 2026 and 8 in April 2026, but it adds to the city's robust research landscape. Indianapolis currently hosts 839 actively recruiting clinical trials across 381 research facilities.

May brings several high-profile new trials to Indianapolis, including significant Phase 2 and Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Novo Nordisk A/S is initiating a notable Phase 3 study, NCT07567001, "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This trial aims for 5,610 participants to evaluate the safety and effect of NNC0487-0111 in individuals with Heart Failure with preserved or mildly reduced Ejection Fraction and excess body weight.
• Indiana University is sponsoring NCT07576881, "Impact of Standardization on Outcomes Following Cervical Ripening," a Phase 2/Phase 3 study involving 1,158 participants. The primary purpose of this study is to determine if vaginal delivery rate is impacted by the use of standardized methods of cervical ripening, with additional maternal and fetal outcomes also being evaluated.
• Eli Lilly and Company is leading NCT07602582, "A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT)." This Phase 3 study, with 550 participants, aims to determine if participants who previously took donanemab receive clinical benefit from annual doses.
• Another Eli Lilly and Company study, NCT07589595, "A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)," is a Phase 2 trial involving 350 participants. Its main purpose is to evaluate whether treatment with donanemab slows the progression of cognitive and functional decline.
• Janssen Research & Development, LLC is sponsoring NCT07572006, "A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies." This Phase 1 study, with 280 participants, will assess the safety, tolerability, and suitable dose of JNJ-95804306 for these conditions.

New trials this month are exploring a range of conditions, with new studies opening for Alzheimer disease, amyloid, cognitive dysfunction, dementia, heart failure, hematologic neoplasms, Lewy body disease, obesity, plaque, amyloid, and pregnancy. Drug trials account for the largest share of new studies, with 4 new drug trials, followed by 2 device trials, 1 combination product trial, and 1 other type of study.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research. 2 of the 7 new trials launched this month are actively seeking healthy volunteers. Across Indianapolis, a total of 73 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Indianapolis's Leading Research Facilities

Indianapolis is home to some of Indiana's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Indiana University (103 trials)
• Riley Hospital for Children (65 trials)
• Indiana University School of Medicine (42 trials)
• Indiana University/Melvin and Bren Simon Cancer Center (42 trials)
• Indiana University Melvin and Bren Simon Comprehensive Cancer Center (27 trials)
• Indiana University Health University Hospital (20 trials)
• Saint Catherine Hospital (20 trials)
• IU Health Methodist Hospital (19 trials)
• Indiana University Health (18 trials)
• Community Health Network (16 trials)
• Dawes Fretzin Clinical Research Group, LLC (16 trials)
• Ascension Saint Vincent Indianapolis Hospital (15 trials)

These institutions offer a broad spectrum of research, from oncology at the Indiana University Melvin and Bren Simon Cancer Centers, to pediatric care at Riley Hospital for Children, and diverse medical fields across the Indiana University Health network.

Broadening Your Search: Nearby Options in Indiana

While Indianapolis offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Indiana. Cities with active trials include Bloomington (6 trials), West Lafayette (3 trials), Fort Wayne (3 trials), Carmel (2 trials), Columbus (1 trial), Hammond (1 trial), Valparaiso (1 trial), and Clarksville (1 trial).

Participation in clinical trials is open to a diverse range of individuals. Of the 7 new trials launched this month, 5 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 1 new trial is female-only. Academic institutions like Indiana University (2 trials) and industry sponsors such as Eli Lilly and Company (2 trials), Novo Nordisk A/S (2 trials), and Janssen Research & Development, LLC (1 trial) are driving significant research efforts in the city.

As we move further into spring, Indianapolis's robust research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.